104 related articles for article (PubMed ID: 16002303)
1. New therapeutic options for the metabolic syndrome: what's next?
Flordellis CS; Ilias I; Papavassiliou AG
Trends Endocrinol Metab; 2005 Aug; 16(6):254-60. PubMed ID: 16002303
[TBL] [Abstract][Full Text] [Related]
2. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
3. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
Yamauchi T; Kadowaki T
Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
[TBL] [Abstract][Full Text] [Related]
4. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
Rana JS; Nieuwdorp M; Jukema JW; Kastelein JJ
Diabetes Obes Metab; 2007 May; 9(3):218-32. PubMed ID: 17391148
[TBL] [Abstract][Full Text] [Related]
6. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
7. Obesity and the metabolic syndrome in the elderly--a mini-review.
Lechleitner M
Gerontology; 2008; 54(5):253-9. PubMed ID: 18841025
[TBL] [Abstract][Full Text] [Related]
8. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for vascular injury in the metabolic syndrome.
Yamagishi S; Nakamura K; Jinnouchi Y; Takenaka K; Imaizumi T
Drugs Exp Clin Res; 2005; 31(3):123-9. PubMed ID: 16033251
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome: what's in a name?
Wubben DP; Adams AK
WMJ; 2006 Jul; 105(5):17-20. PubMed ID: 16933408
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways.
Caglayan E; Blaschke F; Takata Y; Hsueh WA
Curr Opin Pharmacol; 2005 Apr; 5(2):135-42. PubMed ID: 15780821
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome.
Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
Grundy SM
J Am Coll Cardiol; 2006 Mar; 47(6):1093-100. PubMed ID: 16545636
[TBL] [Abstract][Full Text] [Related]
15. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Schernthaner GH; Schernthaner G
Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism.
Flachs P; Rossmeisl M; Bryhn M; Kopecky J
Clin Sci (Lond); 2009 Jan; 116(1):1-16. PubMed ID: 19037880
[TBL] [Abstract][Full Text] [Related]
18. The metabolic syndrome and its cardiovascular manifestations.
Sánchez-Torres RJ; Delgado-Osorio H
Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
[TBL] [Abstract][Full Text] [Related]
19. The metabolic syndrome: metabolic changes with vascular consequences.
Wassink AM; Olijhoek JK; Visseren FL
Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
Lebovitz HE
Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
